ATE232109T1 - Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung - Google Patents

Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung

Info

Publication number
ATE232109T1
ATE232109T1 AT94925121T AT94925121T ATE232109T1 AT E232109 T1 ATE232109 T1 AT E232109T1 AT 94925121 T AT94925121 T AT 94925121T AT 94925121 T AT94925121 T AT 94925121T AT E232109 T1 ATE232109 T1 AT E232109T1
Authority
AT
Austria
Prior art keywords
muc
tandem repeats
derivatives
peptides
multiple tandem
Prior art date
Application number
AT94925121T
Other languages
English (en)
Inventor
Olivera J Finn
J Darrell Fontenot
Ronald C Montelaro
Original Assignee
Olivera J Finn
J Darrell Fontenot
Ronald C Montelaro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olivera J Finn, J Darrell Fontenot, Ronald C Montelaro filed Critical Olivera J Finn
Application granted granted Critical
Publication of ATE232109T1 publication Critical patent/ATE232109T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94925121T 1993-07-30 1994-07-29 Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung ATE232109T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/099,354 US5744144A (en) 1993-07-30 1993-07-30 Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
PCT/US1994/008477 WO1995003825A1 (en) 1993-07-30 1994-07-29 Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof

Publications (1)

Publication Number Publication Date
ATE232109T1 true ATE232109T1 (de) 2003-02-15

Family

ID=22274597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925121T ATE232109T1 (de) 1993-07-30 1994-07-29 Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung

Country Status (7)

Country Link
US (2) US5744144A (de)
EP (1) EP0804231B1 (de)
JP (1) JPH09501159A (de)
AT (1) ATE232109T1 (de)
CA (1) CA2167730A1 (de)
DE (1) DE69432109T2 (de)
WO (1) WO1995003825A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
AU703120B2 (en) * 1995-10-20 1999-03-18 University Of Nebraska Board Of Regents Composition and methods for enhancing immune responses mediated by antigen-presenting cells
WO1997028187A2 (en) * 1996-01-31 1997-08-07 The Population Council Multivalent chimeric peptides as microbicides
AU734253B2 (en) * 1996-03-20 2001-06-07 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
WO1997035008A1 (en) * 1996-03-21 1997-09-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chimeric polypeptides for tumor antigen vaccines
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
ES2251028T3 (es) * 1996-05-24 2006-04-16 Chiron Corporation Proteina de fusion de epitopos multiples.
EP0925071A4 (de) * 1996-09-10 2000-09-13 Biomira Inc Therapeutische zusammensetzungen die, entweder einzeln oder kombiniert, ein antiserum gegen gift enthalten zur therapeutischen vorbeugung und therapie von neoplasmen
JP2001502907A (ja) * 1996-10-25 2001-03-06 ダナ―ファーバー キャンサー インスティテュート インク． ムチンが介在した免疫調節
WO1998037095A2 (en) 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
JP2002519669A (ja) * 1998-06-26 2002-07-02 バイオミラ，インコーポレイテッド Ｔ細胞の活性化を検出する方法
JP4820003B2 (ja) * 1998-11-05 2011-11-24 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌の血清マーカーとしてのｓ１００タンパク質および自己抗体
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19906615A1 (de) * 1999-02-17 2000-09-28 Hanisch Franz Georg Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung
GB9904695D0 (en) * 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
DE60131670T2 (de) 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
WO2002062319A2 (en) * 2001-01-19 2002-08-15 Corixa Corporation Microsphere delivery of mucin peptides
CA2441809C (en) 2001-03-27 2014-07-22 Biomira, Inc. Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
EP1383802A4 (de) * 2001-03-30 2005-08-03 Univ California Anti-muc-1-einzelkettenantikörper zum targeting von tumoren
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
EP1436319A2 (de) * 2001-10-18 2004-07-14 Zlatko Ademovic Sich wiederholende motive aus prolinreichen speichelproteinen, mucin und kollagen
WO2003049801A1 (en) * 2001-12-12 2003-06-19 Lewandowski Leon J Photophoretic auto immune stimulation
EP1585960A2 (de) * 2002-01-14 2005-10-19 Vertex Pharmaceuticals Incorporated Mucinimmobiliserte chromatographie
AU2003203079B8 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
US20060069238A1 (en) * 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
ES2368907T3 (es) 2002-04-19 2011-11-23 The Governing Council Of The University Of Toronto Procedimientos y composiciones inmunológicas para el tratamiento de la enfermedad de alzheimer.
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
AU2003258710A1 (en) * 2002-09-05 2004-03-29 Universitat Zu Koln Immunogenic muc1 glycopeptides
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
EP1690937B1 (de) 2003-11-04 2012-10-17 Dnavec Research Inc. Verfahren zur konstruktion einer transgenen dendritischen zelle
ES2623812T3 (es) * 2003-11-12 2017-07-12 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vectores a medida para tratar y prevenir cáncer pancreático
EP1694364B1 (de) * 2003-11-12 2014-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services System zur behandlung und prävention von brustkrebs
DK1697399T3 (en) 2003-12-12 2017-03-06 Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
KR20080013850A (ko) * 2005-02-08 2008-02-13 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 면역원성 분자
NZ563466A (en) 2005-05-27 2009-12-24 Oncimmune Ltd Improved immunoassay methods
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
TWI511738B (zh) * 2005-06-28 2015-12-11 Oncothyreon Inc 以黏液性糖蛋白(ｍｕｃ-１）疫苗治療病人之方法
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2025762A3 (de) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex-Trackingassay
KR20080094910A (ko) 2006-01-17 2008-10-27 디나벡크 가부시키가이샤 신규 단백질 발현계
JPWO2008007581A1 (ja) 2006-07-13 2009-12-10 ディナベック株式会社 非複製型パラミクソウイルス科ウイルスベクター
US20090317414A1 (en) * 2006-07-25 2009-12-24 4G Vaccines Pty Ltd Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
US20100168016A1 (en) * 2007-04-11 2010-07-01 The Jackson Laboratory Diagnosis and treatment of diseases caused by misfolded proteins
US20090124557A1 (en) * 2007-04-16 2009-05-14 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer
SI2148697T1 (sl) * 2007-05-24 2013-01-31 Glaxosmithkline Biologicals S.A. Liofilizirani sestavek, ki vsebuje CpG in WT-1
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
WO2010055900A1 (ja) 2008-11-14 2010-05-20 ディナベック株式会社 樹状細胞の製造方法
BR112012028893A2 (pt) 2010-05-10 2017-12-12 Ascend Biopharmaceuticals Pty Ltd composições imunoestimuladoras e de vacina
BR112013021779A2 (pt) 2011-02-24 2017-09-19 Oncothyreon Inc vacina de glicolipopeptídeo baseada em muc1 com adjuvante.
CA2860599C (en) 2012-01-03 2021-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
WO2016105536A2 (en) * 2014-12-23 2016-06-30 University Of Maryland, Baltimore Muc1 decoy peptides for treatment and prevention of bacterial infections
CA3036799C (en) 2016-09-28 2025-05-13 Bavarian Nordic A/S COMPOSITIONS AND METHODS FOR IMPROVING THE STABILITY OF TRANSGENES IN POXVIRUSES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369816A3 (de) * 1988-11-17 1990-09-12 The University Of Melbourne Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
WO1991008217A1 (en) * 1989-12-05 1991-06-13 The Regents Of The University Of California Human intestinal mucins

Also Published As

Publication number Publication date
DE69432109D1 (de) 2003-03-13
US5827666A (en) 1998-10-27
CA2167730A1 (en) 1995-02-09
EP0804231A1 (de) 1997-11-05
WO1995003825A1 (en) 1995-02-09
DE69432109T2 (de) 2003-11-20
JPH09501159A (ja) 1997-02-04
EP0804231B1 (de) 2003-02-05
EP0804231A4 (de) 1999-08-18
US5744144A (en) 1998-04-28

Similar Documents

Publication Publication Date Title
ATE232109T1 (de) Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
IL124831A0 (en) Ob protein derivatives having prolonged half-life
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
ATE518874T1 (de) Synthetische lipid-a analogen und verwendungen davon
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
IT8449164A1 (it) Composizioni farmaceutiche contenenti sucralfat e procedimento per la loro stabilizzazione
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
MY115211A (en) Novel amino acid derivatives, their preparation and use
BG104267A (en) Aminoterminally incised rantes as haemokin antagonists
CA2201944A1 (en) Analogs of keratinocyte growth factor having enhanced temperature stability
SE9602822D0 (sv) New receptor
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE59410221D1 (de) Rekombinante chladosporium herbarum allergene
DE68905097D1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
IL71870A0 (en) Improved steroid ester preparation
ATE235553T1 (de) Protein p100von menschlichem herpesvirus typ 6, die korrespondierenden dns squenzen, ihre herstellung und verwendung
SE9604439D0 (sv) New receptor
GB2283974A (en) Allatostatins and their use
ATE27822T1 (de) Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus.
DE59711687D1 (de) Antifungische peptide aus scleroderma texense

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties